ReviewInternational journal of hematology2012
Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.
Review in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 92 citations in OpenAlex.
- Combined FXIII-C3 autoantibodies elicit bleeding and complement dysfunction in autoimmune FXIII deficiency.The Journal of clinical investigation · 2026Article
- Factor XIII deficiency: an updated approach to diagnosis and management.Frontiers in medicine · 2026Review
- Prevalence and impact of ECMO cannula colonization: a single center study.Scientific reports · 2025Article
- Detection of factor XIII inhibitors in 33 patients with autoimmune factor XIII deficiency in Japan.International journal of hematology · 2024Article
- Integration of clotting and fibrinolysis: central role of platelets and factor XIIIa.Bioscience reports · 2024Article
- Article
- The in vitro gastrointestinal digestion-associated protein corona of polystyrene nano- and microplastics increases their uptake by human THP-1-derived macrophages.Particle and fibre toxicology · 2024Article
- Factor XIII in the Acute Care Setting and Its Relevance in Obstetric Bleeding.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Review
- Isovitexin Is a Direct Inhibitor ofJournal of microbiology and biotechnology · 2021Article
- Review
- Refractory Duodenal Bleeding Ulcers Successfully Treated with Factor XIII Transfusion.Internal medicine (Tokyo, Japan) · 2021Article
- Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.International journal of molecular sciences · 2021Review
- Acute Occlusion of the Ventriculoperitoneal Shunt Due to Factor XIII Deficiency-related Postoperative Hemorrhage: A Case Report.NMC case report journal · 2021Article
- Article
- Transglutaminases and Obesity in Humans: Association ofInternational journal of molecular sciences · 2020Article
- Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients.Vascular health and risk management · 2020Article
- Recurrent Hematomas following a Revision Total Hip Arthroplasty in Acquired Coagulation Factor XIII Deficiency.Case reports in orthopedics · 2019Article
- Molecular Imaging of Factor XIII Activity for the Early Detection of Mouse Coronary Microvascular Disease.Theranostics · 2019Article
- Inherited genetic predispositions in F13A1 and F13B genes predict abdominal adhesion formation: identification of gender prognostic indicators.Scientific reports · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Factor XIII (FXIII) is a transglutaminase consisting of two catalytic A subunits (FXIII-A) and two non-catalytic B subunits (FXIII-B) in plasma. FXIII-B protects FXIII-A from its clearance. FXIII-A is also present as a homodimer inside megakaryocytes/platelets and monocytes/macrophages. Although possible functions of intracellular FXIII-A have been proposed, these remain to be established. Intra- and extra-cellular FXIIIs support platelet adhesion and spreading as well as clot retraction, suggesting that FXIII is important for the stabilization of platelet-fibrin clots. Intra- and extra-cellular FXIIIs also support immobilization and killing of bacteria as well as phagocytosis by macrophages. Thus, FXIII may function in innate immunity. Congenital FXIII deficiency due to defective F13-A genes manifests as a life-long bleeding tendency, abnormal wound healing, and recurrent miscarriage. Although congenital FXIII-B deficiency used to be thought rare, reports of such cases have increased recently. As the bleeding tendency is often mild, patients with FXIII-B deficiency may be overlooked by physicians. Patients with acquired FXIII deficiency, in particular those with autoimmune hemorrhaphilia due to anti-FXIII antibodies, are on the increase, at least in Japan. It is important to diagnose such cases as early as possible, and to treat them with immunosuppression in combination with FXIII replacement therapy as their bleeding symptoms can be life-threatening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.